What Does Nektar Therapeutics Do?

Total employees
HeadquartersSan Francisco
Founded1990

Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative new medicines in areas of high unmet medical need. Nektar leverages its expertise in polymer chemistry, antibody engineering, and drug design to create novel drug candidates. Their research and development pipeline primarily includes investigational medicines in immunology and oncology, aiming to provide meaningful new therapies to patients. Key programs include rezpegaldesleukin (rezpeg) for autoimmune diseases and NKTR-255, an IL-15 receptor agonist for oncology.

Where Is Nektar Therapeutics's Headquarters?

HQ Function

The San Francisco headquarters serves as the central hub for Nektar's corporate operations, primary research and development activities, strategic planning, clinical development, and administrative functions.

Notable Features:

Located in a modern biomedical research park, the facility likely includes state-of-the-art laboratories, collaborative workspaces, and advanced research equipment necessary for drug discovery and development.

Work Culture:

The work culture at Nektar's HQ is characterized by a strong emphasis on scientific innovation, collaboration among multidisciplinary teams, and a shared commitment to advancing patient care through novel therapeutics. It's a dynamic environment driven by cutting-edge research in a competitive biotech landscape.

HQ Significance:

Its location in Mission Bay places Nektar within a dense ecosystem of academic research institutions (like UCSF), other biotech and pharmaceutical companies, and venture capital, fostering collaboration and access to talent. This strategic positioning is crucial for innovation and staying at the forefront of biopharmaceutical development.

Values Reflected in HQ: The headquarters' design and location likely reflect Nektar's core values of innovation, scientific excellence, collaboration, and a commitment to developing impactful medicines.

Location:

Nektar Therapeutics' primary physical operations, including R&D, corporate functions, and manufacturing, are based in the United States (San Francisco, CA, and Huntsville, AL). While direct international office presence has been streamlined, Nektar's global reach is evident through its clinical trial operations, which often involve sites and investigators in multiple countries across North America, Europe, and potentially other regions, depending on the specific drug development program. The company also engages in collaborations and licensing agreements that may extend the reach of its technology and products globally.

Street Address:

455 Mission Bay Boulevard South

City:

San Francisco

State/Province:

California

Country:

USA

Where Else Does Nektar Therapeutics Operate Around the World?

Huntsville, Alabama/USA

Address: 1112 Church Street NW, Huntsville, AL 35801, USA

The Huntsville location leverages regional strengths in manufacturing and technical expertise. It plays a critical role in Nektar's ability to scale up production of its innovative therapies and ensure quality control.

Buying Intent Signals for Nektar Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Nektar Therapeutics? Meet the Executive Team

As of April 2025, Nektar Therapeutics' leadership includes:

Howard W. Robin - President & Chief Executive Officer, Member of the Board of Directors
Sandra Gardiner - Senior Vice President and Chief Financial Officer
Jonathan Zalevsky, Ph.D. - Chief Research and Development Officer
Dimitry S.A. Nuyten, M.D., Ph.D. - Chief Medical Officer
John Northcott - Chief Commercial Officer
Mark A. Wilson - Senior Vice President, General Counsel and Corporate Secretary

Who's Investing in Nektar Therapeutics?

Nektar Therapeutics has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock Inc.
State Street Corporation
Invus Public Equities, L.P.
Perceptive Advisors LLC

What Leadership Changes Has Nektar Therapeutics Seen Recently?

Hire3
Exits2

Nektar Therapeutics has experienced significant leadership changes in the past 12 months (approx. May 2023 - May 2024), appointing a new Chief Financial Officer, Chief Medical Officer, and Chief Commercial Officer, while seeing departures in the CFO and CMO roles. These changes suggest a period of strategic realignment and team rebuilding.

Departures

Jillian B. Thomsen, Jillian B. Thomsen departed as Chief Financial Officer.
Brian L. Kotzin, M.D., Brian L. Kotzin retired as Chief Medical Officer.

New Appointments:

Sandra Gardiner, Sandra Gardiner appointed as permanent Chief Financial Officer (previously Interim CFO from Nov 2023).
Dimitry S.A. Nuyten, M.D., Ph.D., Dimitry S.A. Nuyten appointed as new Chief Medical Officer.
John Northcott, John Northcott appointed as new Chief Commercial Officer.

What Technology (Tech Stack) Is Used byNektar Therapeutics?

Discover the tools Nektar Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Nektar Therapeutics Email Formats and Examples

Nektar Therapeutics most commonly uses the email format of first initial followed by last name. Understanding common email patterns can be useful for professional communication.

[first_initial][last]@nektar.com

Format

jdoe@nektar.com

Example

75%

Success rate

What's the Latest News About Nektar Therapeutics?

Nektar TherapeuticsMay 9, 2024

Nektar Therapeutics Reports First Quarter 2024 Financial Results

Nektar Therapeutics announced its financial results for the first quarter of 2024 and provided updates on its clinical pipeline, including progress on rezpegaldesleukin (rezpeg) in atopic dermatitis and alopecia areata, and NKTR-255 in oncology....more

Nektar TherapeuticsApril 1, 2024

Nektar Therapeutics Presents New Preclinical Data for NKTR-255 at the American Association for Cancer Research (AACR) Annual Meeting 2024

Nektar shared new preclinical findings for NKTR-255, its IL-15 receptor agonist, at the AACR 2024. The data highlighted NKTR-255's mechanism of action and its potential to enhance anti-tumor immune responses, particularly in combination therapies....more

Nektar TherapeuticsFebruary 20, 2024

Nektar Therapeutics Appoints Sandra Gardiner as Chief Financial Officer

Nektar Therapeutics officially named Sandra Gardiner as its Senior Vice President and Chief Financial Officer. Ms. Gardiner had been serving as Interim CFO since November 2023....more

Nektar TherapeuticsJanuary 4, 2024

Nektar Announces First Patient Dosed in Phase 1b Study of NKTR-255 in Combination with an Anti-PD1 in Patients with Head and Neck Cancer Who Are Checkpoint Naive

Nektar announced the dosing of the first patient in a Phase 1b clinical study evaluating NKTR-255 in combination with an anti-PD1 therapy for patients with squamous cell carcinoma of the head and neck who have not previously received checkpoint inhibitor therapy....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Nektar Therapeutics, are just a search away.